Full text is available at the source.
Abstract
The study evaluates the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
- Tirzepatide is being compared to GLP-1 receptor agonists in this evaluation.
- The focus is on patients with type 2 diabetes and existing atherosclerotic cardiovascular disease.
- The primary outcome of interest is the incidence of major adverse cardiovascular events over one year.
Simplified